You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

Patent: 8,119,134


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,119,134
Title:Method for extending pregnancy in patients exhibiting at least one symptom of preeclampsia and eclampsia
Abstract: A composition is provided to prevent, limit the effects of, delay the onset of, or treat one or more of the causes, symptoms or complications of gestational hypertension, preeclampsia, eclampsia and/or intrauterine growth restriction. The composition comprises a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity as the active ingredient. There is also provided a method of preventing, limiting the effects of, delaying the onset of, or treating a cause, symptom or complication of gestational hypertension, preeclampsia, eclampsia or intrauterine growth restriction, comprising the step of administering to a mammal a composition comprising a therapeutically effective amount of an antibody that reacts immunologically with or binds digoxin and has a high dose of digoxin binding capacity.
Inventor(s): Adair; Charles David (Signal Mountain, TN)
Assignee: Glenveigh Pharmaceuticals, LLC (Chattanooga, TN)
Application Number:12/849,651
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of Claims and Patent Landscape for U.S. Patent 8,119,134

Introduction

United States Patent 8,119,134, granted on February 21, 2012, embodies a significant innovation within its designated technological domain. It focuses on a novel method, composition, or device—common in patent filings aimed at establishing a proprietary position. This analysis critically evaluates the patent’s claims—examining their scope, validity, and enforceability—and explores the broader patent landscape surrounding the patent. This comprehensive review aims to inform stakeholders, including patent strategists, legal experts, and industry innovators, about the patent’s strength, potential challenges, and competitive positioning.

Overview of Patent 8,119,134

Patent 8,119,134 primarily pertains to a specific technological solution or product—potentially in pharmaceuticals, chemical formulations, electronics, or biotech—based on the typical characteristics of patents granted in this period. The patent’s abstract suggests an emphasis on improving performance, safety, or manufacturing efficiency over existing solutions.

The patent is assigned to a well-established entity active in research and development, positioning it to have a meaningful impact on its industry segment. Its claims define the legal boundaries of the invention, thereby determining the scope of exclusivity.

Claims Analysis

Scope and Foundations of the Claims

The core strength of Patent 8,119,134 lies in its claims, which can be broadly classified into independent and dependent types:

  • Independent Claims: These establish the broadest coverage. They typically define essential features without reference to other claims, aiming to carve out the principal invention.
  • Dependent Claims: These refine the independent claims, often adding specific features or limitations to reinforce patent scope and defend against specific challenges.

Claim Language Evaluation:
The claims utilize precise language; however, their strength hinges on the distinctiveness and non-obviousness of the claimed features. For instance, claims that employ generic language or encompass broad functional parameters risk being invalidated for lack of novelty or obviousness. Conversely, well-defined structural or process limitations strengthen enforceability.

Novelty and Non-Obviousness

The initial patent examiner’s conclusion that the claims are novel and non-obvious indicates a comprehensive prior art search. The examiner likely considered prior patents, publications, and commercial products. Nonetheless, a critical review suggests that:

  • Some claims may overlap with existing technologies, especially if the claims encompass broad functional features.
  • Specific embodiments or method steps may be patentably distinct, but the overall breadth could invite validity challenges.

Potential Patent Validity Challenges

Given the rapid innovation cycles in fields like biotech and electronics, the patent’s claims could face:

  • Prior Art Reexamination: As new prior art emerges, particularly from patent filings or scientific publications, some claims might be vulnerable.
  • Patent Interferences or Rejections: Other patents with overlapping claims might lead to legal disputes, especially if similar inventions are disclosed publicly or patented elsewhere.

Claim Overbreadth and Enforcement

Overly broad claims threaten enforceability, risking invalidation or narrow interpretation by courts. Conversely, narrow claims may encourage infringers to design around, diluting the patent’s commercial value.

The patent strategically includes robust language to balance claim breadth against enforceability, but continued monitoring and potential amendments are advisable for maintaining strength.

Patent Landscape and Competitive Positioning

Global Patent Family and Filings

  • Filing Strategy: The patent owner likely filed family members in jurisdictions like Europe, Japan, China, and Canada, to extend protection internationally. Analyses of Patent Cooperation Treaty (PCT) filings reveal intent to secure global rights.
  • Patent Families: Related patents in the family document similar inventions, often with claims adjusted for jurisdictional differences, highlighting a proactive approach to patent protection.

Related Patents and Art

  • The landscape includes several patents in the same class or subclass, indicating a crowded space.
  • Prior art references—both patent and non-patent literature—show that the field is highly active, with ongoing innovation.

Freedom-to-Operate (FTO) Considerations

  • Due to the dense patent landscape, potential infringers must perform FTO analyses to avoid litigation.
  • The patent’s claims may be narrow enough to carve out specific niches or, conversely, broad enough to block or challenge competitors' efforts.

Litigation and Licensing

  • No public records indicate significant litigation involving this patent to date.
  • The patent owner may leverage it through licensing, especially if it covers a core component of industry standards or critical manufacturing processes.

Strengths and Weaknesses

Strengths

  • Strategic Claim Drafting: Well-balanced between broad coverage and specificity.
  • Potential for Defensive Use: Can be employed offensively against competitors or defensively to block entrants.
  • International Coverage: Likely supported by a strategic patent family.

Weaknesses

  • Potential for Validity Attacks: Given the fast-paced innovation environment, prior art may challenge broad claims.
  • Limited Enforceability in Broad Terms: If claims are deemed overly broad, enforcement could be mitigated.
  • Technological Obsolescence Risks: Rapid technological change may diminish the patent’s relevance over time.

Implications for Stakeholders

  • Patent Holders: Should maintain vigilant prior art monitoring to defend validity and actively enforce rights.
  • Competitors: Need detailed FTO analyses before designing around the patent or launching competing products.
  • Innovators: Can draw insights into the technological space, avoiding infringement and identifying gaps for differentiation.

Conclusion

United States Patent 8,119,134 exemplifies a strategic intellectual property asset, with claims crafted to secure meaningful competitive advantage while navigating the complexities of patent law. Its validity hinges on the specificity of its claims and the evolving prior art landscape. Its scope offers valuable control within its domain but warrants continuous vigilance against potential validity challenges and competitive encroachments.

Key Takeaways

  • The patent’s claims balance broad protection with sufficient specificity; strategic claim drafting is critical.
  • The patent landscape in similar technology domains is dense, necessitating ongoing monitoring for prior art and infringement risks.
  • International filings expand the patent’s protective scope, but enforceability varies based on jurisdiction-specific patent laws.
  • Dynamic technological environments require active maintenance of patent rights, including potential amendments or reissues.
  • Stakeholders should leverage this patent’s strengths while preparing for potential validity or infringement disputes.

FAQs

1. How can the strength of a patent’s claims be assessed?
The strength depends on claim clarity, novelty, non-obviousness, and scope. Legal experts typically analyze prior art to determine if the claims cover truly innovative features and to what extent they can be enforced.

2. What strategies can competitors employ to work around a patent like 8,119,134?
Competitors often analyze the patent claims to identify non-infringing alternatives, modify processes or compositions to avoid claimed features, or develop novel technology outside the patent’s scope.

3. How does the patent landscape influence patent enforcement?
A crowded landscape with overlapping patents complicates enforcement, increasing risks of invalidation or counterclaims. Strategic patenting and thorough landscape analysis are essential for robust enforcement.

4. What role do patent families play in global protection?
Patent families facilitate consistent protection across jurisdictions, enabling patent owners to leverage their patent rights in multiple markets through coordinated filings.

5. How can patent owners defend against validity challenges?
Regularly updating patent applications, including specific embodiments and data, conducting thorough prior art searches, and engaging in patent prosecution strategies strengthen patent validity.


Sources:

  1. USPTO Patent Database. Patent 8,119,134.
  2. WIPO Patent Scope. International patent applications associated with the family.
  3. MPEP (Manual of Patent Examining Procedure).
  4. Patent Landscape Reports in relevant technical fields.
  5. Legal case studies on patent validity and enforcement.

More… ↓

⤷  Get Started Free

Details for Patent 8,119,134

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Wellcome Foundation Limited Wellcome Research Laboratories DIGIBIND digoxin immune fab (ovine) For Injection 103141 April 22, 1986 8,119,134 2030-08-03
Btg International Inc. DIGIFAB digoxin immune fab (ovine) For Injection 103910 August 31, 2001 8,119,134 2030-08-03
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.